HLA-A and metastatic melanoma: Contrary to expanded CTLs, TCR transgenic T cells targeting HLA-A*02:01 restricted NY-ESO1 have already shown drastic clinical responses in patients with refractory metastatic melanoma, synovial cell sarcoma, and multiple myeloma [128,129].